BQ1

Bedaquiline

Find entries where: BQ1

is present as a standalone ligand in 9 entries

Find related ligands:

Chemical Component Summary
Name	Bedaquiline
Identifiers	(1R,2S)-1-(6-bromanyl-2-methoxy-quinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenyl-butan-2-ol
Formula	C₃₂ H₃₁ Br N₂ O₂
Molecular Weight	555.505
Type	NON-POLYMER
Isomeric SMILES	CN(C)CC[C@@](c1cccc2c1cccc2)([C@H](c3ccccc3)c4cc5cc(ccc5nc4OC)Br)O
InChI	InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
InChIKey	QUIJNHUBAXPXFS-XLJNKUFUSA-N

Chemical Details
Formal Charge	0
Atom Count	68
Chiral Atom Count	2
Bond Count	72
Aromatic Bond Count	28

Drug Info: DrugBank

DrugBank ID	DB08903
Name	Bedaquiline
Groups	approved
Description	Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity.[A261866] Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP.[A261866] Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB).[L48506] Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome.[A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.[A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866]
Synonyms	Bédaquiline Bedaquilina Bedaquiline 1-(6-Bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol Bedaquilinum Bedaquiline fumarate
Brand Names	Sirturo
Indication	Bedaquiline is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.[L48506] This indication is approved under FDA accelerated approval based on time to sputum culture conversion. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.[L48506]
Categories	Anti-Bacterial Agents Anti-Infective Agents Antiinfectives for Systemic Use Antimycobacterials Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Diarylquinoline Antimycobacterial Drugs for Treatment of Tuberculosis Heterocyclic Compounds, Fused-Ring Moderate Risk QTc-Prolonging Agents QTc Prolonging Agents Quinolines
ATC-Code	J04AK05
CAS number	843663-66-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
ATP synthase subunit c	MDPTIAAGALIGGGLIMAGGAIGAGIGDGVAGNALISGVARQPEAQGRLF...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
Alpha-1-acid glycoprotein 1	MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF...	unknown	binder

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682